What is HC Wainwright’s Forecast for MRKR Q1 Earnings?

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for Marker Therapeutics in a report released on Friday, March 20th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Marker Therapeutics’ Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.30) EPS and FY2030 earnings at ($0.75) EPS.

Several other research firms have also recently issued reports on MRKR. Wall Street Zen upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. Zacks Research downgraded Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Marker Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $11.25.

Marker Therapeutics Stock Performance

MRKR stock opened at $1.31 on Monday. The company has a 50 day moving average price of $1.58 and a two-hundred day moving average price of $1.31. The stock has a market capitalization of $21.84 million, a P/E ratio of -1.54 and a beta of 1.42. Marker Therapeutics has a one year low of $0.81 and a one year high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last posted its quarterly earnings data on Wednesday, March 18th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.17. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 80.86%. The business had revenue of $1.10 million during the quarter, compared to analyst estimates of $0.68 million.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. NewEdge Advisors LLC acquired a new position in Marker Therapeutics during the fourth quarter valued at approximately $222,000. Jane Street Group LLC acquired a new stake in shares of Marker Therapeutics in the fourth quarter worth $60,000. Boyer Financial Services Inc. purchased a new position in shares of Marker Therapeutics in the 4th quarter valued at $57,000. Two Sigma Investments LP purchased a new position in shares of Marker Therapeutics in the 3rd quarter valued at $33,000. Finally, XTX Topco Ltd lifted its holdings in shares of Marker Therapeutics by 166.6% during the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after acquiring an additional 36,269 shares in the last quarter. Hedge funds and other institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.